BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35780112)

  • 21. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review.
    Miller FH; Lopes Vendrami C; Gabr A; Horowitz JM; Kelahan LC; Riaz A; Salem R; Lewandowski RJ
    Radiographics; 2021 Oct; 41(6):1802-1818. PubMed ID: 34559587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes of Radiological Treatment Modalities of Hepatocellular Carcinoma: A Single-Center Experience from Saudi Arabia.
    Dahlan YM; Shirah BH; Alghamdi AS; Al Kenawi AA; Sanai FM
    Gulf J Oncolog; 2022 May; 1(39):56-62. PubMed ID: 35695347
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
    Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
    J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.
    Mosconi C; Cappelli A; Pettinato C; Golfieri R
    World J Hepatol; 2015 Apr; 7(5):738-52. PubMed ID: 25914774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial Radioembolization (TARE) Agents beyond
    Bouvry C; Palard X; Edeline J; Ardisson V; Loyer P; Garin E; Lepareur N
    Biomed Res Int; 2018; 2018():1435302. PubMed ID: 30687734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis.
    Brown AM; Kassab I; Massani M; Townsend W; Singal AG; Soydal C; Moreno-Luna L; Roberts LR; Chen VL; Parikh ND
    Cancer Med; 2023 Feb; 12(3):2590-2599. PubMed ID: 35943116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    J Comp Eff Res; 2018 Mar; 7(3):209-221. PubMed ID: 29231047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis.
    Andreozzi G; Lorenzoni V; Bargellini I; Cioni R; Turchetti G
    Cardiovasc Intervent Radiol; 2023 Mar; 46(3):319-326. PubMed ID: 36599950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers.
    Colombo GL; Cammà C; Attili AF; Ganga R; Gaeta GB; Brancaccio G; Franzini JM; Volpe M; Turchetti G
    Ther Clin Risk Manag; 2015; 11():1603-12. PubMed ID: 26527877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.